knowledge -WSS

knowledge

author：explore 2025-10-02 13:40:59 - browse：38

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Pancreatic cancer is often deadly, but new discoveries are raising hope

hotspot

WSS

Covid silver lining: Unprecedented look at human immune system

Oral obesity drug from Viking Therapeutics hits key early target

Extensive review finds private equity owners jack up cost of care

U.K. decision on ALS drug has neurologists, advocates up in arms

US jobless claims fall again as labor market continues to flash strength

When a patient nears the end, a feared therapy can comfort

focus

knowledge

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Drug companies' payments and gifts affect physicians' prescribing

Dobbs anniversary: the lost opportunity of abortion as health care

Hormonal contraceptives don’t actually treat endometriosis

In age of alternative facts, a scholarly course on calling out crap

Pancreatic cancer is often deadly, but new discoveries are raising hope

As demand for Covid shots wanes, Moderna seeks its next success

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Walensky prepares to leave CDC — and Congress — behind

There’s a way to spot data fakery. All journals should be using it

focus

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Extensive review finds private equity owners jack up cost of care

Dementia risk linked to living in disadvantaged areas: Study

Mystery swirls around US soldier who entered North Korea days ago, officials say

U.K. decision on ALS drug has neurologists, advocates up in arms

explore

explore

hotspot

knowledge